Clinical Trials

Biogen’s Alzheimer’s drug shows growing benefits at 2 years slowing clinical decline by 38%

The latest results also point to stronger treatment effects over time

  • By IPP Bureau | November 20, 2026
Biogen’s experimental Alzheimer’s drug diranersen has demonstrated increasing clinical benefits over two years, with new Phase 2 trial data showing a 38% slowdown in clinical decline among patients receiving the 60 mg twice-yearly regimen.
 
The findings from the CELIA study, presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, offer fresh evidence of the drug’s potential to slow the progression of early Alzheimer's disease.
 
At Week 96, patients receiving the 60 mg regimen recorded a 38% slowing of decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) scale, translating into a 1.09-point treatment difference compared with participants originally assigned to placebo.
 
The latest results also point to stronger treatment effects over time. The 60 mg group showed greater slowing of clinical decline at two years than at 18 months across five of six measures assessing cognition, daily functioning and disease progression.
 
While clinical benefits were observed across all doses studied, the twice-yearly 60 mg regimen delivered the largest treatment effects at the two-year mark.
 
"The two-year data presented at CTAD mark an important milestone for diranersen, demonstrating not only sustained clinical benefit but also an increasing magnitude of effect at two years," said Priya Singhal, Executive Vice President and Head of Development at Biogen. 
 
"These findings strengthen the growing body of evidence supporting tau as a therapeutic target and underscore the potential of diranersen to meaningfully impact disease progression for people living with early Alzheimer's disease."
 
The findings are particularly significant given the progressive nature of Alzheimer's disease, according to investigators involved in the trial.
 
“These are highly encouraging results, particularly given the progressive nature of Alzheimer's disease,” said Lawren VandeVrede, a principal investigator in the Phase 2 CELIA study at the University of California, San Francisco. 
 
“The increasing separation observed between 18 months and two years is remarkable and clinically meaningful. For patients and families, slowing clinical decline means more time in early stages, preserving independence, and remaining connected to the people and experiences that matter most.”
 
The two-year data showed improvements across several clinical measures in patients receiving the 60 mg twice-yearly regimen.
 
On the CDR-SB scale, the treatment effect increased from 26% at Week 76 to 38% at Week 96. The slowing of decline on ADAS-Cog13 rose from 42% to 54%, while the effect on the modified integrated Alzheimer's Disease Rating Scale (iADRS) increased from 30% to 46%.
 
The ADCS-ADL-MCI measure, which assesses daily functioning, showed no treatment effect at 18 months but recorded a 30% effect at two years. The ADCOMS measure increased from 23% to 38%.
 
The results suggest that the clinical benefits of diranersen may continue to strengthen with longer treatment, although the findings are based on analyses from the study's ongoing open-label extension.
 
Diranersen was generally well tolerated through two years, with Biogen reporting no new safety signals.
 
The two-year analysis compared participants who received diranersen during the placebo-controlled phase and continued on the same dose with participants initially assigned to placebo who subsequently entered the extension phase.
 
By Week 96, participants in the original placebo group had received either no doses or a single dose of diranersen after entering the extension, providing a placebo-equivalent comparison.
 
All participants in the extension phase are expected to receive diranersen as the study progresses.
 
Alongside the two-year results, Biogen presented additional 18-month placebo-controlled clinical and biomarker findings from CELIA.
 
An analysis of patients receiving the twice-yearly 60 mg dose showed preferential effects in memory, orientation and executive function.
 
The drug also produced substantial reductions in tau PET signal across the brain, as well as in cerebrospinal fluid (CSF) p-tau181 and plasma p-tau217 — biomarkers associated with Alzheimer's disease.
 
Diranersen is an investigational antisense oligonucleotide (ASO) therapy designed to target tau, a protein closely associated with the development and progression of Alzheimer's disease.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.